Venture capital investment in brain-computer interfaces has exceeded $3.2B across 34+ disclosed funding rounds. Neuralink leads with over $1.3 billion raised at a $9.7 billion valuation, followed by Synchron ($345M), Blackrock Neurotech ($250M+), and Precision Neuroscience ($183M+). This page provides a complete breakdown of every tracked BCI funding round, the top-funded companies, and the investors backing the next generation of neural interfaces — sourced from bciintel.com's proprietary database.
The largest funding rounds in BCI history reflect growing investor confidence in the commercial viability of neural interfaces. Neuralink dominates the top of the list, but Synchron, Blackrock Neurotech, and Precision Neuroscience have all raised significant capital to advance their clinical programs.
| # | Company | Round | Amount | Valuation | Lead Investors | Date |
|---|---|---|---|---|---|---|
| 1 | Neuralink | Series E | $650M | $9B | ARK Invest, Sequoia Capital, Founders Fund | 2025-06-02 |
| 2 | Neuralink | Series D | $323M | $5B | Founders Fund | 2023-08-01 |
| 3 | Merge Labs | Seed | $252M | $850M | OpenAI | 2026-01-15 |
| 4 | Science Corporation | Series C | $230M | $1.5B | Lightspeed, Khosla Ventures | 2026-03-05 |
| 5 | Neuralink | Series C | $205M | $2.5B | Vy Capital, Google Ventures, DFJ Growth | 2021-11-01 |
| 6 | Blackrock Neurotech | Majority stake (Tether) | $200M | -- | Tether | 2024-04-29 |
| 7 | Synchron | Series D | $200M | -- | Double Point Ventures | 2025-11-06 |
| 8 | NeuroPace | IPO | $140M | -- | Public markets (Nasdaq: NPCE) | 2021-04-22 |
| 9 | MindMaze | Series C | $105M | -- | undisclosed | 2021-09-01 |
| 10 | Science Corporation | Series B | $103.6M | -- | Khosla Ventures | 2025-03-28 |
Total capital raised is a key indicator of which BCI companies have the runway to reach commercial approval. Developing implantable neural interfaces requires sustained investment across R&D, clinical trials, regulatory submissions, and manufacturing scale-up.
| # | Company | Total Funding | Valuation | HQ | Focus Area |
|---|---|---|---|---|---|
| 1 | Neuralink Corp | $1.3B+ | $9.7B | Austin, TX, USA | invasive |
| 2 | Saluda Medical | $668M | -- | Artarmon, NSW, Australia (US HQ: Bloomington, MN, USA) | DBS |
| 3 | Science Corporation | $490M | $1.5B (2026 Series C) | San Francisco, CA, USA | invasive |
| 4 | Nalu Medical | $446M | -- | Carlsbad, CA, USA | DBS |
| 5 | BrainCo | $370M | $1.3B+ (pre-IPO 2026) | Hangzhou, China (US office: Somerville, MA, USA) | non-invasive |
| 6 | MindMaze | $348M | $1.5B (2021) | Lausanne, Switzerland | non-invasive |
| 7 | Synchron | $345M | -- | New York, NY, USA | invasive |
| 8 | Merge Labs | $252M | $850M (2026 Seed) | San Francisco, CA, USA | non-invasive |
| 9 | Blackrock Neurotech | $250M+ | $350M | Salt Lake City, UT, USA | invasive |
| 10 | NeuroPace | $250M+ | -- | Mountain View, CA, USA | invasive |
BCI venture capital comes from a mix of deep-tech VC firms, strategic corporate investors, and government funding programs. The investor base has matured significantly since 2023 as clinical results de-risked the sector and attracted growth-stage capital.
With $3.2B+ in tracked funding across 34+ rounds, the BCI sector has crossed the threshold from speculative research bets to growth-stage venture capital. Neuralink's $9.7 billion valuation and Synchron's $345 million in cumulative funding demonstrate that institutional investors are pricing in commercial outcomes, not just scientific potential.
The next wave of BCI investment will be driven by FDA approval milestones, initial revenue from commercial devices, and expansion into non-medical applications. Companies that reach regulatory approval first will attract disproportionate follow-on capital.
BCI is the highest-conviction deep-tech investment theme in neuroscience.
Funding data sourced from SEC filings, Crunchbase, PitchBook, company press releases, and bciintel.com's proprietary database (34+ rounds tracked). Valuations reflect latest disclosed or reported figures. Totals may undercount due to undisclosed rounds. Last verified: April 2026.